Journal of Anesthesia

, Volume 33, Issue 1, pp 90–95 | Cite as

Preoperative continuation of aspirin administration in patients undergoing major abdominal malignancy surgery

  • Kazumi OnoEmail author
  • Hidekuni Hidaka
  • Masuya Sato
  • Hideki Nakatsuka
Original Article



In contrast to that in a nonoperative setting, it has been shown that perioperative administration of aspirin did not decrease the rate of death or myocardial infarction but increased major bleeding risk. Since these conflicting results might be due to concurrent use of anticoagulants and a lower thrombotic risk of patients, this cohort study was carried out for patients at a high thrombotic risk without concurrent use of anticoagulants.


Medical records for patients who underwent major abdominal malignancy surgery and who were on a preoperative antiplatelet regimen were reviewed. The patients were divided into two groups according to perioperative antiplatelet management: administration of all preoperative antiplatelet agent-suspended (no aspirin) group and only aspirin administration-continued (aspirin) group. The incidence of symptomatic thromboembolic events, frequency of exogenous blood transfusion within 30 days after surgery and the amount of intraoperative bleeding were compared between the two groups.


After propensity score matching, 105 patients of each group were matched. The incidence of perioperative thromboembolic events in the no-aspirin group was significantly higher than that in the aspirin group [7/105 (6.7%) vs 0/105 (0%), 95% CI 1.44–∞, P = 0.016]. In contrast, neither the frequency of exogenous transfusion [21.0% vs 11.4%, 95% CI 0.88–4.38 P = 0.110] nor the amount of intraoperative bleeding [median (interquartile range), ml: 230 (70–500) vs 208 (50–500), P = 0.325] was different between the two groups.


Although the sample size is relatively small, our findings suggest that continuation of aspirin administration is likely to reduce the thrombotic risk but unlikely to increase the bleeding risk of patients who undergo major abdominal surgery for malignancy.


Perioperative Aspirin Thromboembolism 


  1. 1.
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002;324:71–86.CrossRefGoogle Scholar
  2. 2.
    Giuseppe GK, Biondi-Zoccai GGL, Lotrionte M, Agostoni p, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systemic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667–74.CrossRefGoogle Scholar
  3. 3.
    Baigent C, Blackwell L, Collins R. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849–60.CrossRefGoogle Scholar
  4. 4.
    Bürger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding with its continuation-review and meta-analysis. J Int Med. 2005;257:399–414.CrossRefGoogle Scholar
  5. 5.
    Oscarsson A, Gupta A, Fredrickson M, Järhult J, Nyström M, Pettersson E, Darvish B, Krook H, Swahn E, Eintrei C. To continue or discontinue aspirin in the perioperative period: a randomized controlled clinical trial. Br J Anaesth. 2010;104:305–12.CrossRefGoogle Scholar
  6. 6.
    Mantz Samama CM, Tubach F, Devereaux PJ, Collet JP, Albaladejo P, Cholley B, Nizard R, Barré J, Priou V, Poirier N, Mignon A, Schlumberger S, Longrois D, Aubrun F, Farése ME, Ravaud P, Steg PG. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective noncardiac surgery: the multicenter randomized, blinded, placebo-controlled, STRATAGEM trial. Br J Anaesth. 2011;107:899–910.CrossRefGoogle Scholar
  7. 7.
    Devereaux PJ, Mikobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurtz A, Villa JC, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Chan MTV, Tiboni M, Cook D, Kumar PA, Gorget P, Malaga G, Fleishmann E, Amir M, Eikelboom J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O, Srinathan S, Graham M, Pasin L, Chow C, Petti S, Chrolavicius S, Yusuf S. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014;370:1504–13.CrossRefGoogle Scholar
  8. 8.
    Gerstein N, Carey MC, Cigarroa JE, Schulman P. Perioperative aspirin management after POISE-2: some answers, but questions remain. Anesth Anag. 2015;120:570–5.CrossRefGoogle Scholar
  9. 9.
    Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–23.CrossRefGoogle Scholar
  10. 10.
    Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70:926–38.CrossRefGoogle Scholar
  11. 11.
    Ono K, Hidaka H, Koyama Y, Ishii K, Taguchi S, Kosaka M, Okazaki N, Tanimoto W, Katayama A. Effects of heparin bridging anticoagulation on perioperative bleeding and thromboembolic risks in patients undergoing abdominal malignancy surgery. J Anesth. 2016;30:723–6.CrossRefGoogle Scholar
  12. 12.
    Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399–424.CrossRefGoogle Scholar
  13. 13.
    Olmos A, Govindasamy P. Propensity score: a practical introduction using R. J MultiDiscip Eval. 2015;11:68–88.Google Scholar
  14. 14.
    Kikura M, Oikawa F, Yamamoto K, Iwamoto T, Tanaka KA, Sato S, Landesberg G. Myocardial infarction and cerebrovascular accident following non-cardiac surgery: differences in postoperative temporal distribution and risk factors. J Thromb Haemost. 2008;6:742–8.CrossRefGoogle Scholar
  15. 15.
    Kunisawa S, Ikai H, Imanaka Y. Incidence and prevention of postoperative venous thromboembolism: are they meaningful quality indicators in Japanese care settings? Worl J Surg. 2012;36:280–6.CrossRefGoogle Scholar
  16. 16.
    Pulmonary embolism prevention (PEP) trial collaborative group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet. 2000;355:1295–302.CrossRefGoogle Scholar
  17. 17.
    Steinberg BA, Kim S, Piccini JP, Fonarow GC, Lopes RD, Thomas L, Ezekowitz MD, Ansell J, Kowey P, Singer DE, Gersh B, Mahaffey KW, Hylek E, GO AS, Chang P, Peterson ED. Use and associated risks of concomitant aspirin therapy with oral anticoagulants in patients with atrial fibrillation. Insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry. Circulation. 2013;128:721–8.CrossRefGoogle Scholar
  18. 18.
    Graham MM, Sessler BDI, Parlow JL, Biccard BM, Guyatt G, Leslie K, Chan MTV, Meyhoff CS, Xavier D, Sigmani A, Kumar PA, Mrkobrada M, Cook DJ, Tandon V, Alvarez-Garcia J, Villar JC, Painter TW, Landoni G, Fleischmann E, Lamy A, Whitlock R, Manach YL, Aphang-Lam M, Cata JP, Gao P, Terblanche NCS, Pamana PV, Jamieson KA, Bessissow A, Mendoza GR, Ramirez S, Diemunsch PA, Yusuf S, Devereaux PJ. Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery. Ann Intern Med. 2018;68:237–44.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Anesthesiologists 2018

Authors and Affiliations

  1. 1.Department of Anesthesiology and Intensive Care MedicineKawasaki Medical SchoolKurashikiJapan
  2. 2.Fukuyama City HospitalFukuyamaJapan

Personalised recommendations